These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

91 related items for PubMed ID: 26376140

  • 1. Out, Out--Making Amyloid's Candle Briefer.
    Comenzo RL.
    N Engl J Med; 2015 Sep 17; 373(12):1167-9. PubMed ID: 26376140
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lovat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jakob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP, Hawkins PN.
    Nature; 2002 May 16; 417(6886):254-9. PubMed ID: 12015594
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component.
    Kolstoe SE, Ridha BH, Bellotti V, Wang N, Robinson CV, Crutch SJ, Keir G, Kukkastenvehmas R, Gallimore JR, Hutchinson WL, Hawkins PN, Wood SP, Rossor MN, Pepys MB.
    Proc Natl Acad Sci U S A; 2009 May 05; 106(18):7619-23. PubMed ID: 19372378
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Targeted treatment for amyloidosis.
    Pepys-Vered ME, Pepys MB.
    Isr Med Assoc J; 2014 May 05; 16(5):277-80. PubMed ID: 24979830
    [No Abstract] [Full Text] [Related]

  • 8. Immunoradiometric assay for human serum amyloid P component.
    Millar DJ, Hutchinson WL, Pepys MB.
    J Immunol Methods; 2011 Aug 31; 371(1-2):18-24. PubMed ID: 21708157
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Drug targets for amyloidosis.
    Kolstoe SE, Wood SP.
    Biochem Soc Trans; 2010 Apr 31; 38(2):466-70. PubMed ID: 20298204
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Amyloidosis: a clinico-pathophysiological synopsis.
    Hirschfield GM.
    Semin Cell Dev Biol; 2004 Feb 31; 15(1):39-44. PubMed ID: 15036205
    [Abstract] [Full Text] [Related]

  • 14. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab.
    Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D.
    Arthritis Rheum; 2002 Oct 31; 46(10):2571-3. PubMed ID: 12384913
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Down-regulation of the major circulating precursors of proteins deposited in secondary amyloidosis by a recombinant mouse interleukin-1 receptor antagonist.
    Grehan S, Herbert J, Whitehead AS.
    Eur J Immunol; 1997 Oct 31; 27(10):2593-9. PubMed ID: 9368615
    [Abstract] [Full Text] [Related]

  • 17. [New trends in the treatment of amyloidosis].
    Martínez-Valle F, Gironella-Mesa M, Solans-Laqué R.
    Med Clin (Barc); 2012 May 26; 138(15):667-72. PubMed ID: 22197598
    [Abstract] [Full Text] [Related]

  • 18. Infliximab in the treatment of amyloidosis secondary to Crohn's disease.
    Cabezuelo JB, Egea JP, Ramos F, Torrella E, Muray S, Alcázar C.
    Nefrologia; 2012 May 14; 32(3):385-8. PubMed ID: 22592423
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.